

Pharmaceutical Crystals

Science and Engineering

Edited by

Tonglei Li

*Department of Industrial and Physical Pharmacy, Purdue University
West Lafayette, IN, USA*

Alessandra Mattei

*AbbVie Inc.
North Chicago, IL, USA*

WILEY

Contents

List of Contributors *xiii*

Preface *xv*

1	Crystallography	<i>1</i>
	<i>Susan M. Reutzel-Edens and Peter Müller</i>	
1.1	Introduction	<i>1</i>
1.2	History	<i>6</i>
1.3	Symmetry	<i>7</i>
1.3.1	Symmetry in Two Dimensions	<i>7</i>
1.3.2	Symmetry and Translation	<i>11</i>
1.3.3	Symmetry in Three Dimensions	<i>12</i>
1.3.4	Metric Symmetry of the Crystal Lattice	<i>13</i>
1.3.5	Conventions and Symbols	<i>14</i>
1.3.6	Fractional Coordinates	<i>15</i>
1.3.7	Symmetry in Reciprocal Space	<i>15</i>
1.4	Principles of X-ray Diffraction	<i>17</i>
1.4.1	Bragg's Law	<i>17</i>
1.4.2	Diffraction Geometry	<i>19</i>
1.4.3	Ewald Construction	<i>19</i>
1.4.4	Structure Factors	<i>21</i>
1.4.5	Statistical Intensity Distribution	<i>22</i>
1.4.6	Data Collection	<i>23</i>
1.5	Structure Determination	<i>24</i>
1.5.1	Space Group Determination	<i>24</i>
1.5.2	Phase Problem and Structure Solution	<i>25</i>
1.5.3	Structure Refinement	<i>28</i>
1.5.3.1	Resonant Scattering and Absolute Structure	<i>32</i>
1.6	Powder Methods	<i>33</i>
1.6.1	Powder Diffraction	<i>34</i>
1.6.2	NMR Crystallography	<i>35</i>

1.7	Crystal Structure Prediction	39
1.8	Crystallographic Databases	41
1.9	Conclusions	42
	References	43
2	Nucleation	47
	<i>Junbo Gong and Weiwei Tang</i>	
2.1	Introduction	47
2.2	Classical Nucleation Theory	48
2.2.1	Thermodynamics	48
2.2.2	Kinetics of Nucleation	51
2.2.3	Metastable Zone	53
2.2.4	Induction Time	58
2.2.5	Heterogeneous Nucleation	60
2.3	Nonclassical Nucleation	63
2.3.1	Two-Step Mechanism	63
2.3.2	Prenucleation Cluster Pathway	66
2.4	Application of Primary Nucleation	66
2.4.1	Understanding and Control of Polymorphism	66
2.4.2	Liquid–Liquid Phase Separation	71
2.5	Secondary Nucleation	73
2.5.1	Origin from Solution	74
2.5.2	Origin from Crystals	75
2.5.3	Kinetics	76
2.5.4	Application to Continuous Crystallization	76
2.5.5	Crystal Size Distribution	79
2.5.6	Seeding	80
2.6	Summary	81
	References	82
3	Solid-state Characterization Techniques	89
	<i>Ann Newman and Robert Wenslow</i>	
3.1	Introduction	89
3.2	Techniques	90
3.2.1	X-ray Powder Diffraction (XRPD)	90
3.2.2	Thermal Methods	94
3.2.2.1	Differential Scanning Calorimetry	94
3.2.2.2	Thermogravimetric Analysis (TGA)	95
3.2.3	Spectroscopy	97
3.2.3.1	Infrared (IR)	97
3.2.3.2	Raman Spectroscopy	99
3.2.3.3	Solid-state Nuclear Magnetic Resonance (SSNMR)	101

3.2.4	Water Sorption	105
3.2.5	Microscopy	106
3.3	Case Study LY334370 Hydrochloride (HCl)	109
3.4	Summary	114
	References	114
4	Intermolecular Interactions and Computational Modeling	123
	<i>Alessandra Mattei and Tonglei Li</i>	
4.1	Introduction	123
4.2	Foundation of Intermolecular Interactions	124
4.2.1	Electrostatic Interactions	125
4.2.2	van der Waals Interactions	126
4.2.3	Hydrogen-bonding Interactions	127
4.2.4	$\pi-\pi$ Interactions	129
4.3	Intermolecular Interactions in Organic Crystals	130
4.3.1	Approaches to Crystal Packing Description	130
4.3.2	Impact of Intermolecular Interactions on Crystal Packing	136
4.3.3	Impact of Intermolecular Interactions on Crystal Properties	138
4.4	Techniques for Intermolecular Interactions Evaluation	140
4.4.1	Crystallography	140
4.4.2	Spectroscopy	141
4.4.3	Computational Methods	142
4.4.3.1	Lattice Energy	144
4.4.3.2	Interaction Energy of Molecular Pairs from Crystal Structures	147
4.5	Advances in Understanding Intermolecular Interactions	149
4.5.1	Crystal Structure Prediction	150
4.5.2	Electronic Structural Analysis	152
	References	160
5	Polymorphism and Phase Transitions	169
	<i>Haichen Nie and Stephen R. Byrn</i>	
5.1	Concepts and Overview	169
5.2	Thermodynamic Principles of Polymorphic Systems	175
5.2.1	Monotropy and Enantiotropy	176
5.2.2	Phase Rule	179
5.2.3	Phase Diagrams	179
5.2.4	Phase Stability Rule	182
5.2.4.1	Heat of Transition Rule	182
5.2.4.2	Heat of Fusion Rule	182
5.2.4.3	Entropy of Fusion Rule	183
5.2.4.4	Heat Capacity Rule	183
5.2.4.5	Density Rule	183

5.2.4.6	Infrared Rule	183
5.2.5	Crystallization of Polymorphs	184
5.2.5.1	Ostwald's Rule of Stages	184
5.2.5.2	Nucleation	184
5.3	Stabilities and Phase Transition	189
5.3.1	Thermodynamic Stability	189
5.3.2	Chemical Stability	189
5.3.3	Polymorphic Interconversions of Pharmaceuticals	192
5.3.3.1	Effects of Heat, Compression, and Grinding on Polymorphic Transformation	192
5.3.3.2	Solution-mediated Phase Transformation of Drugs	193
5.4	Impact on Bioavailability by Polymorphs	194
5.5	Regulatory Consideration of Polymorphism	196
5.6	Novel Approaches for Preparing Solid State Forms	199
5.6.1	High-throughput Crystallization Method	200
5.6.2	Capillary Growth Methods	200
5.6.3	Laser-induced Nucleation	201
5.6.4	Heteronucleation on Single Crystal Substrates	201
5.6.5	Polymer Heteronucleation	201
5.7	Hydrates and Solvates	202
5.7.1	Thermodynamics of Hydrates	203
5.7.2	Formation of Hydrates	204
5.7.3	Desolvation Reactions	205
5.7.4	Phase Transition of Solvates/Hydrates in Formulation and Process Development	207
5.8	Summary	209
	References	210
6	Measurement and Mathematical Relationships of Cocrystal Thermodynamic Properties	223
	<i>Gislaine Kuminek, Katie L. Cavanagh, and Nair Rodríguez-Hornedo</i>	
6.1	Introduction	223
6.2	Structural and Thermodynamic Properties	224
6.2.1	Structural Properties	224
6.2.2	Thermodynamic Properties	226
6.2.2.1	Cocrystal K_{sp} and Solubility	226
6.2.2.2	Transition Points	229
6.2.2.3	Supersaturation Index Diagrams	231
6.2.3	A Word of Caution About C_{max} Obtained from Kinetic Studies	232
6.3	Determination of Cocrystal Thermodynamic Stability and Supersaturation Index	234
6.3.1	K_{eu} Measurement and Relationships Between K_{sp} , S_{CC} , and SA	234
6.3.2	Cocrystal Solubility and K_{sp}	241

6.3.3	Cocrystal Supersaturation Index and Drug Solubilization	243
6.4	What Phase Solubility Diagrams Reveal	246
6.5	Cocrystal Discovery and Formation	249
6.5.1	Molecular Interactions That Play an Important Role in Cocrystal Discovery	249
6.5.2	Thermodynamics of Cocrystal Formation Provide Valuable Insight into the Conditions Where Cocrystals May Form	251
6.6	Cocrystal Solubility Dependence on Ionization and Solubilization of Cocrystal Components	253
6.6.1	Mathematical Forms of Cocrystal Solubility and Stability	253
6.6.2	General Solubility Expressions in Terms of the Sum of Equilibrium Concentrations	257
6.6.3	Applications	258
6.7	Conclusions and Outlook	265
	References	265
7	Mechanical Properties	273
	<i>Changquan Calvin Sun</i>	
7.1	Introduction	273
7.1.1	Importance of Mechanical Properties in Pharmaceutical Manufacturing	273
7.1.2	Basic Concepts Related to Mechanical Properties	274
7.1.2.1	Stress, Strain, and Poisson's Ratio	274
7.1.2.2	Elasticity, Plasticity, and Brittleness	276
7.1.2.3	Classification of Mechanical Response	277
7.2	Characterization of Mechanical Properties	278
7.2.1	Experimental Techniques	278
7.2.1.1	Single Crystals	278
7.2.1.2	Bulk Powders	281
7.2.1.3	Tablet Mechanical Properties	282
7.3	Structure–Property Relationship	284
7.3.1	Anisotropy of Organic Crystals	284
7.3.2	Crystal Plasticity, Elasticity, and Fracture	286
7.3.3	Role of Dislocation on Mechanical Properties	287
7.3.4	Effects of Crystal Size and Shape on Mechanical Behavior	289
7.4	Conclusion and Future Outlook	290
	References	291
8	Primary Processing of Organic Crystals	297
	<i>Peter L.D. Wildfong, Rahul V. Haware, Ting Xu, and Kenneth R. Morris</i>	
8.1	Introduction	297
8.1.1	Solid Form	297
8.1.2	Morphology	298

8.2	Primary Manufacturing: Processing Materials to Yield Drug Substance	300
8.2.1	Crystallization (Solidification Processing)	301
8.2.1.1	Solvent Power	303
8.2.1.2	Solvent Classification	305
8.2.1.3	Batch Crystallization	307
8.2.1.4	Continuous Crystallization	308
8.2.2	Filtration and Washing	309
8.2.3	Drying (Removal of Crystallization Solvent)	313
8.2.4	Preliminary Particle Sizing	315
8.3	Challenges During Solidification Processing	319
8.3.1	Polymorphism	320
8.3.1.1	Cooling Crystallization	322
8.3.1.2	Solvent Selection	325
8.3.1.3	Antisolvent Crystallization	328
8.3.1.4	Selective Crystallization Using Additives	328
8.3.2	Hydrate and Organic Solvate Formation	329
8.3.2.1	Hydrate Formation	329
8.3.2.2	Organic Solvate Formation	335
8.3.3	Solvent-mediated Transformations (SMTs)	337
8.3.4	Morphology/Habit Control	342
8.3.4.1	Predicting Solvent Effects on Crystal Habit	343
8.3.4.2	Influence of Morphology on Surface Wetting	346
8.3.5	Crystallization Process Control	349
8.4	Summary and Concluding Remarks	350
	References	351
9	Secondary Processing of Organic Crystals	361
	<i>Peter L.D. Wildfong, Rahul V. Haware, Ting Xu, and Kenneth R. Morris</i>	
9.1	Introduction	361
9.1.1	Structure and Symmetry	361
9.1.2	Process-induced Transformations (PITs) in 2° Manufacturing	362
9.2	Secondary Manufacturing—Processing Materials to Yield Drug Products	365
9.2.1	Milling of Organic Crystals	366
9.2.1.1	Materials Properties Influencing Milling	366
9.2.1.2	Physical Transformations Associated with Milling	371
9.2.1.3	Chemical Transformations Associated with Milling	375
9.2.2	Pharmaceutical Blending	378
9.2.3	Granulation of Pharmaceutical Materials	382
9.2.3.1	Wet Granulation	384
9.2.3.2	Potential Transformations During Wet Granulation	385

9.2.3.3	Hydration and Dehydration	385
9.2.3.4	Solvent-mediated Transformations (SMT)	388
9.2.3.5	Polymorphic Transitions During Granulation	390
9.2.3.6	Salt Breaking	392
9.2.3.7	Formulation Considerations in Wet Granulation	392
9.2.3.8	Risk Assessment and Summary	394
9.2.4	Consolidation of Organic Crystals	395
9.2.4.1	Materials Properties Contributing to Effective Consolidation	397
9.2.4.2	Structural and Molecular Properties Contributing to Effective Consolidation	402
9.2.4.3	Macroscopic Properties Affecting Effective Consolidation	403
9.2.4.4	Compaction-induced Material Transformations	404
9.2.4.5	Compression Temperature and Material Transformation	407
9.2.5	Data Management Approaches	408
9.3	Summary and Concluding Remarks	411
9.3.1	Development History	411
9.3.2	Risk Assessment	412
	References	412

10	Chemical Stability and Reaction	427
	<i>Alessandra Mattei and Tonglei Li</i>	
10.1	Introduction	427
10.2	Overview of Organic Solid-state Reactions	429
10.2.1	Photochemical Reactions	431
10.2.2	Thermal Reactions	432
10.2.3	Mechanochemical Reactions	433
10.2.4	Hydrolysis Reactions	434
10.2.5	Oxidative Reactions	434
10.3	Mechanisms of Organic Solid-state Reactions	436
10.3.1	General Theoretical Concepts	436
10.3.2	Crystal Packing Effects on the Course of Organic Solid-state Reactions	438
10.3.2.1	Perfect Crystals and Topochemical Control of Organic Solid-state Reactions	438
10.3.2.2	Crystal Defects and Nontopochemical Control of Organic Solid-state Reactions	440
10.4	Kinetics of Chemical Reactions: From Homogeneous to Heterogeneous Systems	445
10.4.1	Fundamental Principles of Chemical Kinetics	445
10.4.2	Solid-state Reaction Kinetics	446
10.5	Factors Affecting Chemical Stability	448
10.5.1	Moisture	448

10.5.2	Temperature	448
10.5.3	Pharmaceutical Processing	450
10.6	Strategies to Prevent Chemical Reactions	452
10.6.1	Formulation-related Approaches	453
10.6.2	Prodrugs	454
	References	455

11	Crystalline Nanoparticles	463
	<i>Yi Lu, Wei Wu, and Tonglei Li</i>	
11.1	Introduction	463
11.2	Top-down Technology	467
11.2.1	Media Milling (MM)	467
11.2.2	High-pressure Homogenization (HPH)	468
11.3	Bottom-up Technology	471
11.3.1	Precipitation by Solvent–Antisolvent Mixing	471
11.3.1.1	Sonoprecipitation	473
11.3.1.2	CIJP	473
11.3.1.3	HGCP	476
11.3.2	Supercritical Fluid Techniques	476
11.3.2.1	RESS	478
11.3.2.2	SAS	479
11.3.3	Precipitation by Removal of Solvent	479
11.3.3.1	SFL	479
11.3.3.2	CCDF	479
11.4	Nanoparticle Stabilization	480
11.5	Applications	482
11.5.1	Oral Drug Delivery	482
11.5.2	Parenteral Drug Delivery	484
11.5.3	Pulmonary Drug Delivery	485
11.5.4	Ocular Drug Delivery	486
11.5.5	Dermal Drug Delivery	486
11.6	Characterization of Crystalline Nanoparticles	487
11.6.1	Particle Size and Size Distribution	487
11.6.2	Surface Charge	487
11.6.3	Morphology	491
11.6.4	Crystallinity	491
11.6.5	Dissolution	491
	References	492